Related Experiment Videos

The retinoid-inducible gene I: effect on apoptosis and mitogen-activated kinase signal pathways

Shiang-Long Huang1, Rong-Yaun Shyu, Ming-Yang Yeh

  • 1Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.

Anticancer Research
|May 17, 2002
PubMed
Abstract

Insights

Retinoid-inducible gene I (RIG1) fusion proteins demonstrated significant tumor suppressor activity by inhibiting cancer cell growth and inducing apoptosis. RIG1 negatively impacts key mitogen-activated protein kinase pathways, offering potential therapeutic insights.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Retinoid-inducible gene I (RIG1) is a type II tumor suppressor gene.
  • RIG1 was identified in human gastric cancer cells following all-trans retinoic acid treatment.
  • This study investigates the functional activity of the RIG1 gene.

Purpose of the Study:

  • To analyze the impact of RIG1 fusion proteins on cancer cell proliferation.
  • To evaluate the apoptosis-inducing potential of RIG1.
  • To determine RIG1's effect on mitogen-activated protein kinase (MAPK) signaling pathways.

Main Methods:

  • Cancer cell lines (HtTA and TSGH9201) were transfected with RIG1-myc or RIG1-EGFP expression vectors.
  • Cell growth was quantified using bromodeoxyuridine incorporation.
  • Apoptosis was assessed via in situ DNA breakage and apoptotic body formation.
  • MAPK pathway activity was measured using trans-reporting systems.

Main Results:

  • RIG1-myc expression led to reduced cancer cell growth.
  • Both RIG1-EGFP and RIG1-myc induced apoptosis, evidenced by apoptotic bodies and DNA fragmentation.
  • RIG1 suppressed the transactivation activity of Elk1, c-Jun, and CHOP proteins by 80%, 50%, and 88%, respectively.
  • CHOP protein activity was also suppressed in both cell lines expressing RIG1 fusion proteins.

Conclusions:

  • RIG1 fusion proteins exhibit potent growth-suppressive and apoptosis-inducing effects on cancer cells.
  • RIG1 negatively regulates critical MAPK pathways, including ERK, JNK, and p38.
  • These findings highlight RIG1's role as a tumor suppressor and its potential therapeutic implications.

Related Concept Videos